Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

A Novel Anti-HER2 Antibody-Drug Conjugate XMT-1522 for HER2-Positive Breast And Gastric Cancers Resistant to Trastuzumab Emtansine.

Le Joncour V, Martins A, Puhka M, Isola J, Salmikangas M, Laakkonen P, Joensuu H, Barok M.

Mol Cancer Ther. 2019 Jul 10. pii: molcanther.0207.2019. doi: 10.1158/1535-7163.MCT-19-0207. [Epub ahead of print]

PMID:
31292166
2.

Vulnerability of invasive glioblastoma cells to lysosomal membrane destabilization.

Le Joncour V, Filppu P, Hyvönen M, Holopainen M, Turunen SP, Sihto H, Burghardt I, Joensuu H, Tynninen O, Jääskeläinen J, Weller M, Lehti K, Käkelä R, Laakkonen P.

EMBO Mol Med. 2019 Jun;11(6). pii: e9034. doi: 10.15252/emmm.201809034.

3.

Octreotide Conjugates for Tumor Targeting and Imaging.

Figueras E, Martins A, Borbély A, Le Joncour V, Cordella P, Perego R, Modena D, Pagani P, Esposito S, Auciello G, Frese M, Gallinari P, Laakkonen P, Steinkühler C, Sewald N.

Pharmaceutics. 2019 May 7;11(5). pii: E220. doi: 10.3390/pharmaceutics11050220.

4.

Predicting In Vivo Payloads Delivery using a Blood-brain Tumor-barrier in a Dish.

Le Joncour V, Karaman S, Laakkonen PM.

J Vis Exp. 2019 Apr 16;(146). doi: 10.3791/59384.

PMID:
31058900
5.

Anagrelide for Gastrointestinal Stromal Tumor.

Pulkka OP, Gebreyohannes YK, Wozniak A, Mpindi JP, Tynninen O, Icay K, Cervera A, Keskitalo S, Murumägi A, Kulesskiy E, Laaksonen M, Wennerberg K, Varjosalo M, Laakkonen P, Lehtonen R, Hautaniemi S, Kallioniemi O, Schöffski P, Sihto H, Joensuu H.

Clin Cancer Res. 2019 Mar 1;25(5):1676-1687. doi: 10.1158/1078-0432.CCR-18-0815. Epub 2018 Dec 7.

PMID:
30530703
6.

Seek & Destroy, use of targeting peptides for cancer detection and drug delivery.

Le Joncour V, Laakkonen P.

Bioorg Med Chem. 2018 Jun 1;26(10):2797-2806. doi: 10.1016/j.bmc.2017.08.052. Epub 2017 Sep 1. Review.

7.

Motility of glioblastoma cells is driven by netrin-1 induced gain of stemness.

Ylivinkka I, Sihto H, Tynninen O, Hu Y, Laakso A, Kivisaari R, Laakkonen P, Keski-Oja J, Hyytiäinen M.

J Exp Clin Cancer Res. 2017 Jan 9;36(1):9. doi: 10.1186/s13046-016-0482-0.

8.

PP2A Inhibitor PME-1 Drives Kinase Inhibitor Resistance in Glioma Cells.

Kaur A, Denisova OV, Qiao X, Jumppanen M, Peuhu E, Ahmed SU, Raheem O, Haapasalo H, Eriksson J, Chalmers AJ, Laakkonen P, Westermarck J.

Cancer Res. 2016 Dec 1;76(23):7001-7011. Epub 2016 Sep 26.

9.

Fibroblast spheroids as a model to study sustained fibroblast quiescence and their crosstalk with tumor cells.

Salmenperä P, Karhemo PR, Räsänen K, Laakkonen P, Vaheri A.

Exp Cell Res. 2016 Jul 1;345(1):17-24. doi: 10.1016/j.yexcr.2016.05.005. Epub 2016 May 10.

PMID:
27177832
10.

Gene expression analyses of primary melanomas reveal CTHRC1 as an important player in melanoma progression.

Eriksson J, Le Joncour V, Nummela P, Jahkola T, Virolainen S, Laakkonen P, Saksela O, Hölttä E.

Oncotarget. 2016 Mar 22;7(12):15065-92. doi: 10.18632/oncotarget.7604.

11.

Identification and Characterization of Homing Peptides Using In Vivo Peptide Phage Display.

Hyvönen M, Laakkonen P.

Methods Mol Biol. 2015;1324:205-22. doi: 10.1007/978-1-4939-2806-4_14. Review.

PMID:
26202272
12.

Multifunctional porous silicon nanoparticles for cancer theranostics.

Wang CF, Sarparanta MP, Mäkilä EM, Hyvönen ML, Laakkonen PM, Salonen JJ, Hirvonen JT, Airaksinen AJ, Santos HA.

Biomaterials. 2015 Apr;48:108-18. doi: 10.1016/j.biomaterials.2015.01.008. Epub 2015 Feb 11.

PMID:
25701036
13.

Novel target for peptide-based imaging and treatment of brain tumors.

Hyvönen M, Enbäck J, Huhtala T, Lammi J, Sihto H, Weisell J, Joensuu H, Rosenthal-Aizman K, El-Andaloussi S, Langel U, Närvänen A, Bergers G, Laakkonen P.

Mol Cancer Ther. 2014 Apr;13(4):996-1007. doi: 10.1158/1535-7163.MCT-13-0684. Epub 2014 Feb 3.

14.

Tumour homing peptide-functionalized porous silicon nanovectors for cancer therapy.

Kinnari PJ, Hyvönen ML, Mäkilä EM, Kaasalainen MH, Rivinoja A, Salonen JJ, Hirvonen JT, Laakkonen PM, Santos HA.

Biomaterials. 2013 Dec;34(36):9134-41. doi: 10.1016/j.biomaterials.2013.08.034. Epub 2013 Sep 3.

PMID:
24008034
15.

Peptide-based glioma-targeted drug delivery vector gHoPe2.

Eriste E, Kurrikoff K, Suhorutšenko J, Oskolkov N, Copolovici DM, Jones S, Laakkonen P, Howl J, Langel Ü.

Bioconjug Chem. 2013 Mar 20;24(3):305-13. doi: 10.1021/bc300370w. Epub 2013 Feb 19.

PMID:
23350661
16.

Metastasis-associated cell surface oncoproteomics.

Karhemo PR, Hyvönen M, Laakkonen P.

Front Pharmacol. 2012 Nov 7;3:192. doi: 10.3389/fphar.2012.00192. eCollection 2012.

17.

An optimized isolation of biotinylated cell surface proteins reveals novel players in cancer metastasis.

Karhemo PR, Ravela S, Laakso M, Ritamo I, Tatti O, Mäkinen S, Goodison S, Stenman UH, Hölttä E, Hautaniemi S, Valmu L, Lehti K, Laakkonen P.

J Proteomics. 2012 Dec 21;77:87-100. doi: 10.1016/j.jprot.2012.07.009. Epub 2012 Jul 17.

18.

Kaposi's sarcoma herpesvirus lytic replication compromises apoptotic response to p53 reactivation in virus-induced lymphomas.

Sarek G, Ma L, Enbäck J, Järviluoma A, Moreau P, Haas J, Gessain A, Koskinen PJ, Laakkonen P, Ojala PM.

Oncogene. 2013 Feb 28;32(9):1091-8. doi: 10.1038/onc.2012.118. Epub 2012 Apr 2.

PMID:
22469985
19.

Transforming growth factor beta-induced (TGFBI) is an anti-adhesive protein regulating the invasive growth of melanoma cells.

Nummela P, Lammi J, Soikkeli J, Saksela O, Laakkonen P, Hölttä E.

Am J Pathol. 2012 Apr;180(4):1663-74. doi: 10.1016/j.ajpath.2011.12.035. Epub 2012 Feb 9.

PMID:
22326753
20.

An extensive tumor array analysis supports tumor suppressive role for nucleophosmin in breast cancer.

Karhemo PR, Rivinoja A, Lundin J, Hyvönen M, Chernenko A, Lammi J, Sihto H, Lundin M, Heikkilä P, Joensuu H, Bono P, Laakkonen P.

Am J Pathol. 2011 Aug;179(2):1004-14. doi: 10.1016/j.ajpath.2011.04.009. Epub 2011 Jun 2.

21.

High phase retardation by waveguiding in slanted photonic nanostructures.

Ventola K, Tervo J, Laakkonen P, Kuittinen M.

Opt Express. 2011 Jan 3;19(1):241-6. doi: 10.1364/OE.19.000241.

PMID:
21263562
22.

In vivo SPECT/CT imaging of human orthotopic ovarian carcinoma xenografts with 111In-labeled monoclonal antibodies.

Huhtala T, Laakkonen P, Sallinen H, Ylä-Herttuala S, Närvänen A.

Nucl Med Biol. 2010 Nov;37(8):957-64. doi: 10.1016/j.nucmedbio.2010.03.001.

PMID:
21055627
23.

Identification of homing peptides using the in vivo phage display technology.

Rivinoja A, Laakkonen P.

Methods Mol Biol. 2011;683:401-15. doi: 10.1007/978-1-60761-919-2_29.

PMID:
21053146
24.

Identification of novel p53 pathway activating small-molecule compounds reveals unexpected similarities with known therapeutic agents.

Peltonen K, Colis L, Liu H, Jäämaa S, Moore HM, Enbäck J, Laakkonen P, Vaahtokari A, Jones RJ, af Hällström TM, Laiho M.

PLoS One. 2010 Sep 27;5(9):e12996. doi: 10.1371/journal.pone.0012996.

25.

Homing peptides as targeted delivery vehicles.

Laakkonen P, Vuorinen K.

Integr Biol (Camb). 2010 Aug;2(7-8):326-37. doi: 10.1039/c0ib00013b. Epub 2010 Jul 26. Review.

PMID:
20657951
26.

Complex formation between human prostate-specific antigen and protease inhibitors in mouse plasma.

Hekim C, Riipi T, Zhu L, Laakkonen P, Stenman UH, Koistinen H.

Prostate. 2010 Apr 1;70(5):482-90. doi: 10.1002/pros.21082.

PMID:
19937596
27.

Loss of endothelial Tie1 receptor impairs lymphatic vessel development-brief report.

D'Amico G, Korhonen EA, Waltari M, Saharinen P, Laakkonen P, Alitalo K.

Arterioscler Thromb Vasc Biol. 2010 Feb;30(2):207-9. doi: 10.1161/ATVBAHA.109.196618. Epub 2009 Nov 12.

PMID:
19910638
28.

The role of glycodelin in cell differentiation and tumor growth.

Koistinen H, Hautala LC, Seppälä M, Stenman UH, Laakkonen P, Koistinen R.

Scand J Clin Lab Invest. 2009;69(4):452-9. doi: 10.1080/00365510903056023. Review.

PMID:
19551557
29.

Antiangiogenic properties of prostate-specific antigen (PSA).

Mattsson JM, Laakkonen P, Stenman UH, Koistinen H.

Scand J Clin Lab Invest. 2009;69(4):447-51. doi: 10.1080/00365510903056031. Review.

PMID:
19551556
30.

Low-cost fabrication of form-birefringent quarter-wave plates.

Päivänranta B, Passilly N, Pietarinen J, Laakkonen P, Kuittinen M, Tervo J.

Opt Express. 2008 Oct 13;16(21):16334-42.

PMID:
18852739
31.

Glycodelin reduces breast cancer xenograft growth in vivo.

Hautala LC, Koistinen R, Seppälä M, Bützow R, Stenman UH, Laakkonen P, Koistinen H.

Int J Cancer. 2008 Nov 15;123(10):2279-84. doi: 10.1002/ijc.23773. Erratum in: Int J Cancer. 2016 Jan 1;138(1):E1.

32.

Tumor targeting of baculovirus displaying a lymphatic homing peptide.

Mäkelä AR, Enbäck J, Laakkonen JP, Vihinen-Ranta M, Laakkonen P, Oker-Blom C.

J Gene Med. 2008 Sep;10(9):1019-31. doi: 10.1002/jgm.1222.

PMID:
18655234
33.

Development of peptides specifically modulating the activity of KLK2 and KLK3.

Koistinen H, Närvänen A, Pakkala M, Hekim C, Mattsson JM, Zhu L, Laakkonen P, Stenman UH.

Biol Chem. 2008 Jun;389(6):633-42. doi: 10.1515/BC.2008.076. Review.

PMID:
18627344
34.

Gene expression changes associated with the anti-angiogenic activity of kallikrein-related peptidase 3 (KLK3) on human umbilical vein endothelial cells.

Mattsson JM, Laakkonen P, Kilpinen S, Stenman UH, Koistinen H.

Biol Chem. 2008 Jun;389(6):765-71. doi: 10.1515/BC.2008.088.

PMID:
18627292
35.

Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation.

Tammela T, Zarkada G, Wallgard E, Murtomäki A, Suchting S, Wirzenius M, Waltari M, Hellström M, Schomber T, Peltonen R, Freitas C, Duarte A, Isoniemi H, Laakkonen P, Christofori G, Ylä-Herttuala S, Shibuya M, Pytowski B, Eichmann A, Betsholtz C, Alitalo K.

Nature. 2008 Jul 31;454(7204):656-60. doi: 10.1038/nature07083. Epub 2008 Jun 25.

PMID:
18594512
36.

VEGFR-3 expression is restricted to blood and lymphatic vessels in solid tumors.

Petrova TV, Bono P, Holnthoner W, Chesnes J, Pytowski B, Sihto H, Laakkonen P, Heikkilä P, Joensuu H, Alitalo K.

Cancer Cell. 2008 Jun;13(6):554-6. doi: 10.1016/j.ccr.2008.04.022. No abstract available.

37.

Peptide targeting of tumor lymph vessels.

Laakkonen P, Zhang L, Ruoslahti E.

Ann N Y Acad Sci. 2008;1131:37-43. doi: 10.1196/annals.1413.003. Review.

PMID:
18519957
38.

Structural characterization and anti-angiogenic properties of prostate-specific antigen isoforms in seminal fluid.

Mattsson JM, Valmu L, Laakkonen P, Stenman UH, Koistinen H.

Prostate. 2008 Jun 15;68(9):945-54. doi: 10.1002/pros.20751.

PMID:
18386289
39.

Deterministic diffractive diffusers for displays.

Parikka M, Kaikuranta T, Laakkonen P, Lautanen J, Tervo J, Honkanen M, Kuittinen M, Turunen J.

Appl Opt. 2001 May 10;40(14):2239-46.

PMID:
18357231
40.

Electron-beam-fabricated asymmetric transmission gratings for microspectroscopy.

Laakkonen P, Kuittinen M, Simonen J, Turunen J.

Appl Opt. 2000 Jul 1;39(19):3187-91.

PMID:
18349882
41.

Tumour-homing peptides: tools for targeting, imaging and destruction.

Enbäck J, Laakkonen P.

Biochem Soc Trans. 2007 Aug;35(Pt 4):780-3. Review.

PMID:
17635147
42.

Polarization conversion in conical diffraction by metallic and dielectric subwavelength gratings.

Passilly N, Ventola K, Karvinen P, Laakkonen P, Turunen J, Tervo J.

Appl Opt. 2007 Jul 10;46(20):4258-65.

PMID:
17579681
43.

Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas.

Sarek G, Kurki S, Enbäck J, Iotzova G, Haas J, Laakkonen P, Laiho M, Ojala PM.

J Clin Invest. 2007 Apr;117(4):1019-28. Epub 2007 Mar 15.

44.

Replicated slanted gratings with a high refractive index material for in and outcoupling of light.

Levola T, Laakkonen P.

Opt Express. 2007 Mar 5;15(5):2067-74.

PMID:
19532444
45.

A double-sided grating coupler for thin light guides.

Siitonen S, Laakkonen P, Tervo J, Kuittinen M.

Opt Express. 2007 Mar 5;15(5):2008-18.

PMID:
19532439
46.

Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth.

Laakkonen P, Waltari M, Holopainen T, Takahashi T, Pytowski B, Steiner P, Hicklin D, Persaud K, Tonra JR, Witte L, Alitalo K.

Cancer Res. 2007 Jan 15;67(2):593-9.

47.

Double-groove, two-depth grating coupler for light guides.

Laakkonen P, Siitonen S, Kuittinen M.

J Opt Soc Am A Opt Image Sci Vis. 2006 Dec;23(12):3156-61.

PMID:
17106471
48.

Characterization of the Rab8-specific membrane traffic route linked to protrusion formation.

Hattula K, Furuhjelm J, Tikkanen J, Tanhuanpää K, Laakkonen P, Peränen J.

J Cell Sci. 2006 Dec 1;119(Pt 23):4866-77. Epub 2006 Nov 14.

49.

A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer.

Ranki T, Kanerva A, Ristimäki A, Hakkarainen T, Särkioja M, Kangasniemi L, Raki M, Laakkonen P, Goodison S, Hemminki A.

Gene Ther. 2007 Jan;14(1):58-67. Epub 2006 Aug 10.

50.

White LED light coupling into light guides with diffraction gratings.

Siitonen S, Laakkonen P, Vahimaa P, Kuittinen M, Tossavainen N.

Appl Opt. 2006 Apr 20;45(12):2623-30.

PMID:
16633411

Supplemental Content

Loading ...
Support Center